GB2628348A — Amelioration of drug-drug interactions
Assigned to Ontrack Therapeutics Ltd · Expires 2024-09-25 · 2y expired
What this patent protects
A method of ameliorating a drug-drug interaction (DDI) between the compound 4-(6-oxo-2-(trifluoromethyl)-3,6-dihydrochromeno [7,8-d]imidazol-8-yl) benzonitrile (also known as CF3CN), and compounds which are metabolised via the CYP1A2 enzyme. Preferably the compound which is metab…
USPTO Abstract
A method of ameliorating a drug-drug interaction (DDI) between the compound 4-(6-oxo-2-(trifluoromethyl)-3,6-dihydrochromeno [7,8-d]imidazol-8-yl) benzonitrile (also known as CF3CN), and compounds which are metabolised via the CYP1A2 enzyme. Preferably the compound which is metabolised via the CYP1A2 enzyme is a clinical medicament, such as phenacetin.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.